Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.

IF 2.1 3区医学 Q2 UROLOGY & NEPHROLOGY

Current Opinion in Urology Pub Date : 2024-04-11 DOI:10.1097/mou.0000000000001177

Christoph Nössing, Paula Herek, Shahrokh F Shariat, Walter Berger, Bernhard Englinger

引用次数: 0

Abstract

Bladder cancer incidence is on the rise, and until recently, there has been little to no change in treatment regimens over the last 40 years. Hence, it is imperative to work on strategies and approaches to untangle the complexity of intra and inter-tumour heterogeneity of bladder cancer with the aim of improving patient-specific care and treatment outcomes. The focus of this review is therefore to highlight novel targets, advances, and therapy approaches for bladder cancer patients.

查看原文本刊更多论文

膀胱癌精准医学治疗靶点的临床前评估进展。

膀胱癌的发病率呈上升趋势，而直到最近，过去 40 年来治疗方案几乎没有任何变化。因此，当务之急是研究各种策略和方法，以解决膀胱癌肿瘤内和肿瘤间异质性的复杂性，从而改善针对患者的护理和治疗效果。因此，本综述的重点是突出膀胱癌患者的新靶点、进展和治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Urology 医学-泌尿学与肾脏学

CiteScore

5.00

自引率

4.00%

发文量

140

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Urology delivers a broad-based perspective on the most recent and most exciting developments in urology from across the world. Published bimonthly and featuring ten key topics – including focuses on prostate cancer, bladder cancer and minimally invasive urology – the journal’s renowned team of guest editors ensure a balanced, expert assessment of the recently published literature in each respective field with insightful editorials and on-the-mark invited reviews.